{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-014136","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.079910+00:00","generated_at":"2026-05-24T10:41:43.772028+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Foghorn Therapeutics reduces ATM program capacity from $200M to $100M","bullets":["Amendment No. 1 to Sales Agreement with TD Cowen lowers maximum shares to be sold from $200M to $100M.","Other terms of the at-the-market offering program remain unchanged; no new public offering announced.","Amendment effective March 20, 2025; shares sold pursuant to previously effective shelf registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-014136","json":"https://secwatch.observer/filing/0001628280-25-014136.json","markdown":"https://secwatch.observer/filing/0001628280-25-014136.md","text":"https://secwatch.observer/filing/0001628280-25-014136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025014136/0001628280-25-014136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025014136/fhtx-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:41:43.772028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}